On October 14, 2026 Coherus Oncology, Inc. (Nasdaq: CHRS) reported that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab in multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion leaders to join the webcast and provide their clinical perspective.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Webcast Information

When: Wednesday, October 28, 2026, from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time.

To access the web ex, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: View Source

Webcast: View Source

A live and archived webcast will be available on the "Investors" section of the Coherus website and accompanying materials will be available after the webcast at View Source

Please log in approximately 15 minutes before the start of the webcast to ensure a timely connection.

Disclosure Information

Coherus uses the View Source;website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. 

(Press release, Coherus Oncology, OCT 14, 2026, View Source [SID1234673470])

On October 14, 2026 Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) ("Estrella" or the "Company"), a clinical-stage biopharmaceutical company developing CD19- and CD22-targeted ARTEMIS T-cell therapies to treat cancers and autoimmune diseases, reported the activation of a fifth clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial evaluating its investigational product candidate EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL). The new site, Intermountain Health LDS Hospital, in Salt Lake City, Utah, is expected to begin screening and enrolling patients following completion of site initiation activities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Intermountain Health LDS Hospital’s long-standing work in cellular therapy makes it a strong addition to STARLIGHT-1," said Cheng Liu, Ph.D., Chief Executive Officer of Estrella Immunopharma. "Each new site moves the dose-expansion phase forward and brings us closer to defining the path to a future pivotal study for EB103 in patients with R/R B-cell NHL."

The ongoing expansion phase of the Phase I/II clinical trial for EB103 is designed as a multi-center, open-label study intended to further evaluate the safety and efficacy of EB103 at the recommended Phase II dose (RP2D) in subjects (≥ 18 years of age) who have R/R B-cell NHL. Estrella expects that data from this expansion cohort will inform its pivotal trial strategy for EB103. As of the date of this press release, active clinical sites for the trial are UC Davis Comprehensive Cancer Center, Baylor Scott & White Research Institute, Oregon Health & Science University, University Hospitals Cleveland Medical Center, and Intermountain Health LDS Hospital. Further details of the trial can be found at www.clinicaltrials.gov under NCT identifier NCT06343311.

About EB103

EB103, a T-cell therapy, also referred to as Estrella’s "CD19-Redirected ARTEMIS T-cell Therapy," utilizes ARTEMIS technology licensed from Eureka Therapeutics, Inc. (Eureka), Estrella’s parent company. Unlike a traditional CAR-T cell, the unique design of an ARTEMIS T-cell, such as EB103 allows it to be activated and regulated upon engagement with cancer targets through a cellular mechanism that more closely resembles that of an endogenous T-cell receptor. Once infused, EB103 T cells bind to and destroy CD19-positive cancer cells.

(Press release, Estrella Immunopharma, OCT 14, 2026, View Source [SID1234673469])

On October 14, 2026 Pilatus Biosciences, a clinical-stage biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, reported that the first patient has been dosed in Hong Kong, in the hepatocellular carcinoma (HCC) biomarker backfill cohort of its ongoing Phase 1 clinical trial of PLT012.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The dosing follows authorization from the Hong Kong Department of Health in July 2026 to conduct the PLT012 clinical study in Hong Kong. The Hong Kong site, based at the Phase I Clinical Trial Centre under the Department of Clinical Oncology of The Chinese University of Hong Kong, will support the HCC backfill and dose expansion cohorts as part of the broader PLT012 Phase 1 study.

The backfill cohorts are intended to evaluate preliminary clinical activity and generate biomarker data in patients with advanced HCC, including those with underlying liver dysfunction. By integrating clinical outcomes with biomarker findings from this cohort, the study aims to further inform PLT012’s future clinical development and support a deeper understanding of its potential role across the liver disease continuum, from chronic liver dysfunction to malignancy.

PLT012 is a first-in-class investigational monoclonal antibody targeting CD36, a key regulator of lipid metabolism within the tumor microenvironment. By blocking CD36-mediated lipid uptake, PLT012 is designed to reprogram the tumor microenvironment by reducing immunosuppressive cell populations while restoring the activity of antitumor immune cells.

"Dosing the first patient in Hong Kong represents an important milestone for the PLT012 program and for Pilatus as we continue expanding the global clinical development of our lead program," said Raven Lin, Ph.D., Chief Executive Officer and Co-Founder, Pilatus Biosciences. "By collecting clinical and biomarker data from patients with HCC, we aim to better understand PLT012’s broader anti-tumor activity, inform its next stage of development supported by FDA Fast Track Designation, and further explore mechanisms associated with response to immunotherapy in HCC. We appreciate the collaboration of our investigators in Hong Kong."

"There remains a significant need for new treatment approaches for patients with advanced Liver cancers, particularly those with underlying liver dysfunctions," said Stephen Chan, M.D., Principal Investigator and Clinical Professor at the Department of Clinical Oncology of The Chinese University of Hong Kong. "The HCC biomarker backfill cohort will help characterize clinical findings and selected biomarker profile of patients receiving PLT012 treatment. We are pleased to begin dosing patients from Asia in Hong Kong."

The current Hong Kong study cohort forms part of Pilatus’ broader clinical development program for PLT012. Pilatus established its Hong Kong subsidiary earlier this year as part of the Company’s expansion in Asia and is leveraging the region’s clinical research infrastructure to support the developments of PLT012, as well as further academic and metabolic chokepoints immunotherapies strategic collaborations.

About PLT012

PLT012 is a humanized monoclonal antibody designed to selectively block CD36-mediated lipid uptake, a key mechanism driving immunosuppression and immune exclusion within the tumor microenvironment. By targeting lipid metabolism, PLT012 exerts a unique mechanism of action: it depletes immunosuppressive cell populations, including Tregs and pro-tumor macrophages, while simultaneously enhancing antitumor activities of intratumoral NK cell and cytotoxic CD8+ T cell that are otherwise susceptible to lipid-induced exhaustion. In preclinical studies, PLT012 has demonstrated potent monotherapy efficacy in models of liver malignancies, with a favorable safety profile across species. Leveraging its distinct mechanism of action, PLT012 further acts as a potent sensitizer in combination with oncology therapies, effectively overcoming drug resistance in immune "cold" tumors and liver metastases.

(Press release, Pilatus Biosciences, OCT 14, 2026, View Source [SID1234673468])

On October 14, 2026 Ironfist Therapeutics ("Ironfist"), a preclinical-stage company developing a nanomedicine radiopharmaceutical (Tamrada) that selectively targets tumor-associated macrophages without a targeting ligand, reported it will present positive preclinical proof-of-concept results for 177Lu-Tamrada at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM’26), taking place October 17–21, 2026, in Vienna, Austria. In an orthotopic syngeneic model of pancreatic cancer resistant to anti-PD-1 therapy, 177Lu-Tamrada in combination with anti-PD-1 therapy more than doubled survival compared to anti-PD-1 therapy alone.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These preclinical results continue to support our strategy of treating the immune-suppressing microenvironment in cancers," said Jeffrey L. Cleland, PhD, Chief Executive Officer of Ironfist Therapeutics. "In Q1 2027, we plan to begin clinical studies with 64Cu-Tamrada PET imaging, followed by 177Lu-Tamrada treatment in patients whose tumors show Tamrada uptake on PET."

Oral Presentation Details:
Targeted Killing of Tumor Associated Macrophages with a Novel [177Lu]Lu-Nanomedicine Prolongs Survival and Unlocks Checkpoint Inhibition in an Orthotopic Pancreatic Cancer Model
Oral presentation OP-482 | Session 1104: M2M Track – TROP Session – Translational Molecular Imaging & Therapy Committee: Advances in Combination Therapies
Monday, October 19, 2026, 5:35 PM | Hall E2

Pancreatic ductal adenocarcinoma is a difficult-to-treat cancer resistant to checkpoint inhibition and generally considered protected from the immune system. Long-term survival is limited with current treatments. The pancreatic cancer results are consistent with previous positive single-agent results, including tumor inhibition in xenograft and orthotopic 4T1 triple-negative breast cancer models and in PSMA-negative prostate cancer models.

"By killing tumor-associated macrophages (TAMs) and suppressor cells, 177Lu-Tamrada exposes the tumor to the immune system to halt tumor growth and promote survival," said S. Sakura Minami, PhD, Vice President of Translational Medicine and Nonclinical Development. "The cytotoxic effects are confined to the tumor, as shown by localized double-strand DNA breaks, leaving other organs and healthy tissue intact. And unlike other radiopharmaceutical approaches, Tamrada is tumor agnostic because it directly targets the TAMs that protect the tumor from the immune system, stimulate angiogenesis, and generate metastases."

e-Poster Details:
Radiation Dosimetry, Chemistry and Formulation of a Novel [64Cu]Cu-Nanomedicine Radiotracer that Selectively Targets Tumor Associated Macrophages
e-Poster Number: EP-0072
Session: EP-05, During Congress, October 17–21, 2026
Session Title: A: Preclinical and Translational Studies › A1 Medical Preclinical › A15a Preclinical Dosimetry

The e-Poster reports that dosimetry for the imaging agent 64Cu-Tamrada identified red marrow as the dose-limiting organ, with a 240-fold safety factor above the highest proposed human dose of 200 MBq.

"Radiopharmaceuticals have drawn significant interest from large pharma, and Tamrada offers something different: a target-independent way to reach the tumor microenvironment across many cancer types," said Mukul Agarwal, Chief Business Officer of Ironfist Therapeutics. "With clinical studies starting in 2027 and a platform that can carry other isotopes, we look forward to meeting potential partners." To schedule a meeting at EANM’26 or the J.P. Morgan Healthcare Conference in January ’27, contact [email protected].

About Tamrada

Tamrada is designed from the novel nanomedicine technology of hydroxyl dendrimers invented at Johns Hopkins University. The nanomedicine component of Tamrada is comparable in size to an antibody fragment, does not leave the vasculature except in tumors, and has renal and biliary clearance without metabolism. 177Lu-Tamrada provides an additional benefit of a bystander effect by killing adjacent tumor cells. The nanomedicine in Tamrada is amenable to modifications to create a pipeline of radiopharmaceuticals with different radioisotopes beyond lutetium-177, such as actinium-225 or other alpha emitters.

(Press release, Ironfist Therapeutics, OCT 14, 2026, View Source [SID1234673467])

On October 14, 2026 Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, reported their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-clinical performance of a selection of linker technology from Debiopharm’s MultiLINK Linker Technology suite (MLINK Select, MLINK Duo and MLINK HiSol), revealing positive implications for the development of next generation ADCs and for the future of cancer patients that require more innovative therapies to overcome their disease.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Despite remarkable progress in the ADC field, many cancers remain difficult to treat due to biological complexities that challenge current-generation therapies. Tumor heterogeneity can enable cancer cells with low or absent target expression to escape treatment, while acquired resistance to single-payload ADCs may emerge over time and compromise durable responses. Furthermore, premature linker cleavage can lead to systemic payload release and off-target toxicities, restricting the therapeutic index of ADCs. These limitations underscore the urgent need for next-generation ADC technologies, including innovative linker-payload systems and dual-payload linker approaches, designed to address resistance, broaden anti-tumor activity while remaining tolerable, and ultimately improve outcomes for patients facing cancer.

MLINK Select MMAE: Novel Linker-Payload Research

Research results presented at World ADC demonstrated that novel linker MLINK Select releases controlled intracellular MMAE and substantially widens the therapeutic index of vedotin-based MMAE ADCs in preclinical models, while maintaining high-level anti-tumor activity. Notably, efficacy was demonstrated in specific models resistant to approved ADC therapies. Data presented reveal that MLINK Select MMAE achieves: more selective intracellular cleavage, stepwise/controlled MMAE release, higher plasma stability, minimal circulation of free MMAE, improved therapeutic index, and maintenance of anti-tumor activity.

"We recognize the remarkable progress made by ADCs, but many patients, however, continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities. We believe that next generation ADC innovation can make a difference by focusing not only on what is delivered to cancer cells, but also on how it is delivered, particularly regarding linker selection," explained Noemie Luong, Associate Principal Scientist, Debiopharm. "Our preclinical findings demonstrate that precise control of payload release through innovative linker engineering has the potential to expand the therapeutic window while maintaining anti-tumor activity."

MLINK DUO: Synergystic activity with Dual-Payload linker

Strong proof-of-concept data was released for Debiopharm’s next-generation dual-payload ADC, MLINK Duo, a linker technology that allows conjugation of two payloads to the same antibody. Results revealed that our dual-payload ADCs produced synergistic antitumor activity, including in models with low sensitivity to individual payloads, demonstrating the potential to synergistically overcome resistance and tumor heterogeneity. Enhanced efficacy was achieved while preserving critical ADC properties, including plasma stability, antibody pharmacokinetics and a favorable preclinical safety profile.

"With MLINK Duo, we observed the potential to exploit payload synergy while reducing resistance mechanisms," expressed Viktoriia Postupalenko, Senior Scientist/ Project Manager, Drug Research and Development, Debiopharm. "As dual-payload conjugation did not compromise antibody pharmacokinetics, we confirmed that increased payload complexity can be achieved without sacrificing desired ADC properties. By advancing smart dual-payload designs such as with MLINK Duo, we aim to help unlock more effective and better tolerated treatment options for patients fighting cancer."

MLINK HiSol: Unlocking new ADC therapeutic strategies

Further research showcased modular cathepsin B-cleavable MLINK HiSol linkers designed to overcome common ADC development challenges, including payload solubility, stability, aggregation, and efficient intracellular release. The versatility of this linker type was particularly highlighted showing that it is not limited to conventional ADC payloads such as MMAE and exatecan, but can potentially unlock new ADC therapeutic strategies based on targeted pathway inhibition with precision oncology payloads such as ATR inhibitors, CHK1 inhibitors, and NAMPT inhibitors.

"Targeted small-molecule inhibitors are traditionally difficult to use as ADC payloads," Noemie Luong added, "We’re excited that the results with MLINK HiSol are opening the door towards more payload possibilities to help patients fight cancer. Now that we’ve seen early evidence that MLINK HiSol can enable delivery of targeted small-molecule inhibitors, we can explore ADCs beyond conventional cytotoxic mechanisms."

(Press release, Debiopharm, OCT 14, 2026, View Source [SID1234673466])